Glofitamab Cost-Effectiveness: Conditional Reim...

By HEOR Staff Writer

February 17, 2026

Glofitamab Cost-Effectiveness in R/R DLBCL Reimbursement Glofitamab cost-effectiveness analysis by Zorginstituut Nederland supports conditional inclusion of glofitamab (Columvi...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Surge in Obesity Intervention Costs in the Netherlands